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Abstract
Acute ischemic stroke continues to devastate millions of individuals worldwide.
Current treatments work to restore blood flow but not rescue affected tissue.
Our goal was to develop a combination of neuroprotective agents administered
intra-arterially following recanalization to target ischemic tissue. Using C57Bl/6J
male mice, we performed tandem transient ipsilateral middle cerebral/common
carotid artery occlusion, followed by immediate intra-arterial pharmacotherapy
administration through a standardized protocol. Two pharmacotherapy agents,
verapamil and lubeluzole, were selected based on their potential to modulate
different aspects of the ischemic cascade; verapamil, a calcium channel blocker,
works in an acute fashion blocking L-type calcium channels, whereas lubeluzole,
an N-methyl-D-aspartate modulator, works in a delayed fashion blocking intracellular glutamate trafficking. We hypothesized that combination therapy would
provide complimentary and potentially synergistic benefit treating brain tissue
undergoing various stages of injury. Physiological measurements for heart rate
and pulse distention (blood pressure) demonstrated no detrimental effects between groups, suggesting that the combination drug administration is safe. Tissue
analysis demonstrated a significant difference between combination and control
(saline) groups in infarct volume, neuronal health, and astrogliosis. Although a
significant difference in functional outcome was not observed, we did note that
the combination treatment group had a greater percent change from baseline in
forced motor movement as compared with controls. This study demonstrates the
safety and feasibility of intra-arterial combination therapy following successful
recanalization and warrants further study.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Treatment of emergent large vessel occlusion (ELVO) traditionally includes administration of intravenous thrombolytic and/or endovascular thrombectomy
(ET). Although both works to restore blood flow, neither addresses the cellular
death associated with ELVO. Multiple studies have attempted to address the
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issue of rescuing dying neurons in the core and penumbra but most have failed.
Furthermore, compounds that demonstrated positive results in animal models
failed in clinical trials, leaving only thrombolytic and ET as treatment.
WHAT QUESTION DID THIS STUDY ADDRESS?
The objective of this study was to develop a combination of neuroprotective agents
administered intra-arterially (IA) following recanalization to target ischemic tissue. In combination, verapamil, an L-type Ca2+ channel blocker, and lubeluzole,
an N-methyl-D-aspartate modulator, demonstrated no negative physiological
side effects, decreased infarct volume and inflammation, and increased neuronal
survival. Although there was no difference in functional outcome, this is the first
study to demonstrate that combination therapy for the treatment of ELVO is safe
and feasible.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
This is the first study to combine two pharmacotherapy agents for the treatment
of ELVO and demonstrate their safety and efficacy in treating affected tissue.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR
TRANSLATIONAL SCIENCE?
Prior ELVO therapy studies looked to one drug. Stroke is not a one-pathway disease but a multifaceted disease needing treatments on multiple fronts. Using the
US Food and Drug Administration (FDA) approved drugs with established safety
and efficacy profiles removes years of testing. Furthermore, our model of IA drug
delivery mimics the clinical condition, allowing compounds to move more easily
from the bench to bedside.

I N T RO DU CT ION
Acute ischemic stroke is the second leading cause of
death worldwide, affecting 6.5 million individuals.1,2 A
subset of ischemic stroke, emergent large vessel occlusion (ELVO), affects the major cerebrovascular arteries
(internal carotid artery, M1 and M2 of the middle cerebral artery [MCA], anterior cerebral artery, posterior
cerebral artery, basilar artery, and vertebral artery), and
is the most disabling and life-threatening.3–5 Currently,
there is only one US Food and Drug Administration
(FDA) approved drug therapy for ELVO, intravenous
tissue-plasminogen activator (i.v. tPA), but it has shown
limited effect on large vessel occlusions,6 and has significant exclusion criteria (most notably an administration window of 4.5 h from last known normal).7–9
Recent clinical trials using mechanical thrombectomy
(MT), or the endovascular removal of the clot, have
demonstrated increased recanalization rates with fewer
exclusion criteria leading to greater patient benefit.10–12
Although i.v. t-PA and MT have increased the chance of
stroke survival through recanalization, they do not confer neuroprotection/neurorepair. There is a critical need
for neuroprotective and neuroreparative compounds
post-stroke, especially as adjuncts to thrombectomy. A
number of compounds have shown positive preclinical

results (NXY-059, magnesium, and citicoline), but none
have successfully transitioned to the clinic.13–16 This is
attributed to such issues as poor study design, failure to
recanalize, and delayed drug administration.17–19 The
completed ESCAPE trial demonstrated significantly
improved functional outcomes and decreased mortality when patients received MT compared to i.v. tPA.20
Recanalization via MT allows neuroprotective/neuroreparative compounds to be administered directly to the
site of ischemia.
Using prior studies as a guide, we selected a transient model of ischemia (tandem ipsilateral common
carotid/middle cerebral artery occlusion [MCAo]) with
confirmed recanalization. This mimics a distal M1 occlusion in humans. Further, we developed an intra-
arterial (IA) model of pharmacotherapy administration
5 minutes post-recanalization, similar to the moment
immediately following thrombectomy recanalization
where IA drug therapy would be clinically feasible.21
This route of administration also ensured our drug of
interest reached the ischemic tissue mitigating negative
systemic effects and potential crossover to the contralateral hemisphere.21,22 Using this methodology, we have
previously tested two compounds individually to assess
neuroprotection; verapamil, an L-type calcium channel blocker,22 and nitroglycerin,23 a known vasodilator.

INTRA-ARTERIAL COMBINATION THERAPY FOR ISCHEMIC STROKE

Although we saw significant histological, pathological,
and behavioral outcome benefits with each agent, perhaps unsurprisingly, neither agent succeeded in completely reversing the effects of a stroke.22,23 Therefore,
in view of the fact that multiple pathways are known
to induce damage in ischemia, we conclude that one
therapeutic compound is unlikely to be sufficient for
post-stroke neuroprotection. Rather, a combination
of compounds targeting more than one pathway, and,
perhaps, acting in different time scales and/or synergistically, would be optimal. To select potential neuroprotective compounds, we established specific criteria:
(1) prior successful preclinical stroke studies and (2)
mechanisms of action that target different phases of
cellular apoptosis. Based on the aforementioned criteria, verapamil and lubeluzole were selected.22,24–28
Verapamil inhibits the release of intracellular calcium
by blocking L-type calcium channels, one of the earliest
channels to open during cellular apoptosis. Lubeluzole
inhibits extracellular glutamate release through modulation of the N-methyl-D -aspartate (NMDA) receptor,
which is downstream of the L-type calcium channels
in cellular apoptosis. Our combinational approach will
allow us to target both the core and penumbra, two regions of the brain undergoing different stages of cellular apoptosis. The core, or tissue directly fed by the
occluded MCA, will begin cellular apoptosis immediately due to lack of blood flow. Whereas the penumbra,
or tissue receiving blood flow from a watershed region
will have a delayed cellular apoptosis. Using a combinational approach, we are targeting tissue regions
undergoing different phases of cellular apoptosis. We
hypothesize that combination therapy with verapamil
and lubeluzole prevent the various stages of cellular
apoptosis in the affected tissue, providing neuroprotection and improved brain health.

M AT E R I A L S AN D MET H ODS
Animals
Experiments adhered to protocols on file with the
Institutional Care and Use Committee at the University
of Kentucky, and ARRIVE guidelines. Animal studies used 16-w eek-old C57Bl/6J male mice (Jackson
Laboratories). Groups were separated into control
(n = 7; MCAo surgery with IA saline injection), and
combination (n = 7; MCAo surgery with IA verapamil/lubeluzole injection). Verapamil IA dose was
calculated using current clinical dosing of 10 mg in a
70 kg person; dose corresponds to 0.15 mg/kg. 22,27,29,30
Lubeluzole IA dose was calculated using preclinical

  

|

281

dosing of 0.63 mg/kg.24 Flow rate (2.5 µl/min) and injection volume (10 µl) was determined in prior studies.21 Animals were randomized and the experimenter
was blinded for analysis of perfusion, physiological
measurements, behavioral testing, infarct volume, and
immunohistochemistry. Exclusion criteria were rupture of MCA or common carotid artery (CCA) during
surgery, if the animal died during recovery, or did not
meet health standards and were euthanized prior to
study end. Past study morality rates for MCAo surgery
and IA injections are less than 5%, the mortality rate
for the current study was 0%.

Stroke induction: MCAo
To induce an ischemic event, animals were anesthetized using a ketamine/xylazine cocktail, and focal
ischemia was induced for 1 h by MCAo.22,23,27 Briefly,
with the mouse in the supine position, a midline incision was made along the trachea and the left common
carotid artery was exposed. Next, an incision was made
between the lateral portion of the right eye and medial portion of the right ear, and the temporalis muscle
reflected. Then a small burr hole was made over the
MCA, but not rupturing the dura. Occlusion consisted
of a wire filament placed underneath the MCA and
then a vessel clip was attached to the CCA. Ischemia
was confirmed using a laser Doppler Periflux System
5000 with 2-millimeter tip (Perimed). Reperfusion included removal of the wire filament underneath the
MCA and CCA vessel clamp.

IA injection
The IA pharmacotherapy injection occurred 5 min
post-reperfusion. Briefly, 10 min prior to reperfusion
the external and internal carotid arteries (ECA/ICA)
were exposed allowing access to the bifurcation from
the CCA. The distal ECA and ICA were temporarily ligated with 6–0 suture, and a small nick was made in
the ECA distal to the CCA bifurcation. Micro-angio
tubing attached to a Hamilton syringe was inserted
into the nick of the ECA and threaded to the bifurcation. The tubing was temporarily secured using 6–0 suture. The temporary suture at the distal ECA and ICA
were removed. Following reperfusion (5 min), IA injection commenced for 4 min. The methods were previously described.21–23,27 Physiological measurements and
body temperature during the MCAo and IA injection
procedures were monitored using MouseOx Plus (thigh
sensor and rectal probe).
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Behavioral testing

(ANOVA) was performed for time course comparisons
(MouseOx, behavior). Significance is defined as *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001.

Rotor Rod (forced motor movement) was assessed at
baseline (BL; 1 day prior to MCAo and IA pharmacotherapy administration), and post-stroke days (PSDs)
1 and 7. Rotor Rod consisted of three trials on a rotating rod (0–40 rpm) accelerating over 5 min, trials
were averaged for each testing day, PSDs 1 and 7 were
compared to BL to determine percent change. Open
field (free roam movement) was assessed at the same
time points (BL, and PSDs 1 and 7). Open field consisted of a single mouse placed inside an open box
(90 × 90 × 40 cm) for 5 min and allowed to explore
the environment. Total distance (cm) travelled was
captured using Noldus Ethovision XT software and an
infrared camera.

To maximize the applicability of our results, we designed and conducted the study according to STAIR
recommendations for preclinical neuroprotection research.31 Experimenters were blinded and animals were
randomized to groups. As this was an exploratory rather
than confirmatory study, we used young single-sex animals, with a plan for future experiments with mixed
sexes and older animals with comorbidities mimicking
clinical stroke conditions.

Infarct volume

RESULTS

Mice were euthanized on PSD 7 via cervical dislocation
and the isolated brains were flash frozen and sectioned
(Bregma −2, 0, 2, and 4) with a Leica CM 1950 cryostat at
20 µm onto glass slides. Brain sections were stained using
cresyl violet, scanned, and infarct volume measured with
Image J software (National Institutes of Health [NIH]), as
previously described.21,22,26

Perfusion

Immunohistochemistry
Astrogliosis was evaluated using glial fibrillary activating protein (GFAP; 1:1000; Sigma) immunohistochemistry. Mature neuron survival was evaluated using
NeuN (1:500; Abcam) immunohistochemistry. A Nikon
Eclipse Ti microscope with attached to the charge coupled device (CCD) camera and Nikon NIS Element BR
software was used to image stained sections at 20×
magnification. Imaged brain sections were analyzed for
stain intensity via positive pixel density quantification
using Photoshop software. Stroke-affected region was
morphologically identified and corresponds to the core
and peri-infarct, a 500-µm boundary extending from the
edge of the infarct core, medial and lateral to the infarct
within the cortex.

Statistical analysis
Measured variables presented as mean ± SEM. A
Student’s t-test was performed for comparison between
treatment groups (infarct volume and immunohistochemistry). A two-way repeated measures analysis of variance

Compliance with STAIR

Baseline (pre-occlusion) perfusion measurements (laser
Doppler) were set to 100% (solid line; Figure 1a). Post-
occlusion measurements, 5 min after MCAo induction,
demonstrated a decrease of 79.57 ± 2.63% for the control group and 75.63 ± 1.63% for the combination group
(Figure 1a). Although groups were not separated into control or combination until the IA drug injection following
reperfusion, there was a significant reduction (p ≤ 0.0001)
in MCA blood flow for both groups following occlusion,
with no difference between groups.

Physiological measurements
MouseOx Plus physiological measurements for heart rate
(bpm; Figure 1b) were combined for all mice for 0–5 min
(pre-occlusion; 147.98 ± 0.34), and 60–65 min (post-
reperfusion; 145.91 ± 0.37), and demonstrating a nonsignificant decrease of 2 bpm. Groups separated at 70–75 min
(post IA drug injection) into control (149.55 ± 0.44) and
combination (150.55 ± 0.71) groups. Again, there was no
significant difference between groups following IA drug
injection.
Physiological measurements for pulse distention
(µm; Figure 1c) were also combined for all mice for
0–5 min (28.59 ± 0.15), and 60–65 min (32.02 ± 0.23),
demonstrating a significant increase (p ≤ 0.0001) of
4 µm. Groups separated at 70–75 min into control
(27.66 ± 0.30) and combination (30.68 ± 0.25) also show
a significant difference (p ≤ 0.0001) between groups.
Although this significant difference in pulse distention

INTRA-ARTERIAL COMBINATION THERAPY FOR ISCHEMIC STROKE
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F I G U R E 1 (a) Laser Doppler flowmetry measurements
of MCA for control (n = 5) and combination (n = 7), black
line indicates baseline (100%). MouseOx plus physiological
measurements of combined (black), control (red), and combination
(blue) groups. (b) Heart rate in beats per minute (bpm), 0–5 min
(baseline), 60–65 min (recanalization), and 70–75 min (post IA
drug injection). (c) Pulse distention measuring vessel diameter
(µm), 0–5 min (baseline), 60–65 min (recanalization), and 70–75
(post IA drug injection). Functional measurements of control (red)
and combination (blue) groups. (d) Rotor rod percent change from
baseline. (e) Open field percent change from baseline. *Indicates a
p < 0.001. IA, intra-arterially; MCA, middle cerebral artery; PSD,
post-stroke day

was observed, all mice survived and recovered within
normal guidelines.

Behavioral testing
Rotor rod testing for baseline and PSDs 1 and 7 is presented
as a percent change from baseline. On PSD 1, both the
control (98.71 ± 18.83) and combination (72.77 ± 25.80)
groups decreased compared to BL, but there was no difference between groups compared to BL. On PSD 7, performance increased from BL and PSD1 in both the control
(131.44 ± 24.30) and combination (175.25 ± 28.36) groups.
Although no significant difference was observed between
groups, there was a trend toward greater performance in
the combination group (Figure 1d).
Open field testing is presented as percent change
from BL. On PSD 1, both control (46.50 ± 2.33) and combination (38.04 ± 4.64) groups decreased compared to
BL with no significant difference between groups. On
PSD 7, both control (62.78 ± 1.79) and combination
(61.94 ± 5.16) groups increased compared to PSD 1 but
did not recover to BL values. No significant difference
was observed between groups at any testing time point
(Figure 1e).

Infarct volume
Infarct volume analysis using cresyl violet-stained coronal
brain sections from PSD 7 demonstrated a significant difference (p ≤ 0.05) between control IA (20.99 ± 3.51 mm3)
and combination IA (8.27 ± 3.81 mm3) groups
(Figure 2a–c).

Immunohistochemistry
Immunohistochemistry analysis was performed on PSD
7 using 20 µm (3 sections/mouse) coronal brain slices

stained with GFAP (astrocyte marker) and NeuN (neuronal marker). Positive Pixel Density analysis for GFAP
(Figure 2d–f ) demonstrated a significant difference
(p ≤ 0.005) between control IA (16,492.28 ± 2029.77)
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and combination IA (6,515.57 ± 844.34) groups. Positive
Pixel Density analysis for NeuN (Figure 2g–i) demonstrated a significant difference (p ≤ 0.01) between
control IA (7071.07 ± 1505.12) and combination IA
(19,347.53 ± 2763.41) groups.

DI S C US S I O N
Using a clinically relevant transient mouse model
of stroke, we previously developed an IA model of
pharmacotherapy administration following recanalization that ensures our drug of interest reaches the
ischemic tissue.21 Although our prior single drug
studies showed some success, 22,23 the likelihood that
a single drug therapy would have significant clinical
impact on the complex pathological cascade of stroke
is unlikely.

MANISKAS et al.

Therefore, we hypothesized that a combination of
compounds targeting acute and delayed phases of apoptosis would provide greater neuroprotection. We selected
both verapamil for the acute phase with a terminal half-
life of 3–5 h32,33 and lubeluzole for the delayed phase with
a terminal half-life of 20–28 h.28,34,35 Verapamil inhibits
intracellular calcium release through membrane bound
L-type Ca2+ channels, some of the first to open when
blood flow to the brain diminishes, causing a shift in intracellular calcium concentration. This represents the acute
phase of stoke-induced cellular apoptosis and would target the ischemic penumbra still receiving watershed blood
flow. Lubeluzole inhibits extracellular glutamate release
through membrane bound NMDA receptor modulation.
These receptors are downstream of the L-type Ca2+ channels, and represent the delayed phase of stroke-induced
cellular apoptosis targeting the ischemic core, which has
no blood flow.

F I G U R E 2 (a) Quantification of infarct volume and representative images of cresyl violet sections for (b) control IA (n = 7) and (c)
combination IA (n = 7) groups. (d) Quantification of Positive Pixel Density for GFAP within the infarcted region and representative images
for (e) control IA (n = 5) and (f) combination IA (n = 5) groups. (g) Quantification of Positive Pixel Density for NeuN within infarcted region
and representative images for (h) control IA (n = 5) and (i) combination IA (n = 5) groups. *Indicates a p < 0.05, **indicates a p < 0.01 Scale
bar = 100µm. GFAP, glial fibrillary activating protein; IA, intra-arterially

INTRA-ARTERIAL COMBINATION THERAPY FOR ISCHEMIC STROKE

The goal of potential neuroprotective compounds
is to decrease infarct volume through neuron preservation leading to functional abilities equal to pre-
stroke measurements. Here, preliminary results
using a small “n” demonstrated that combination
treatment was safe, feasible, and neuroprotective
when compared to saline control, and importantly,
was physiologically well-t olerated in terms of both
heart rate and pulse distention. Whereas combination animals had a greater pulse distention following IA administration, all animals recovered to BL
values. Functional outcomes demonstrated greater
recovery for combination animals compared to controls in forced motor movement. This is attributed
to the combination having a significant reduction in
infarct volume compared to controls. Likewise, the
combination had a significant increase in mature
neuron survival and a significant reduction in astrogliosis compared to controls.
Present study results were compared to previous
study results to determine if combination IA had greater
benefit than verapamil IA, and nitroglycerin IA.20,21
All three studies demonstrated positive results; significant reduction in infarct volume, significant increase in
mature neuron survival, significant reduction in astrogliosis, and improved functional outcome. In regard to
infarct volume and functional outcome, verapamil IA22
alone demonstrated greater benefit compared to nitroglycerin IA22,23 and current combination IA, but the effect was negligible.
Although overall positive, this study did have limitations. The sample sizes for this exploratory study
were small, and would require larger numbers of animals in future confirmatory studies. Verapamil and
lubeluzole need to be administered IA individually
and compared to an IA combination. If an IA combination is found to be of greater benefit than individual
compounds, a dose response study would be required
to optimize the combination. Finally, although
blinded and randomized, this exploratory study evaluated single-s ex (male) young animals. Future confirmatory studies should examine both sexes, as well as
aged and diseased animals to more closely mimic the
stroke population.
It was the goal of this study to combine two potentially neuroprotective compounds to determine safety,
feasibility, and neuroprotection. This was accomplished
by delivering our compounds of IA immediately following recanalization targeting stroke-affected tissue
directly, and demonstrates this approach may be more
broadly applicable to other potential neuroprotective
agents.
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CONCLUSION
This study successfully demonstrated safety, feasibility,
and neuroprotective potential of combination therapeutics administered IA as an adjunct to ELVO recanalization.
Given the growing utilization of mechanical thrombectomy, these pharmacotherapeutic approaches warrant
further exploration.
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